Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Cipla has reported consolidated financial results for the period ended March 31, 2022
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The new building is expected to be commissioned by 2024. Post the expansion, Nanavati-Max Hospital will be amongst the largest private sector hospital in western India
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
He was previously working as the CEO of IVD business at Trivitron Healthcare and drove its growth through innovation
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
